Sanofi: positive phase III data in IPT
The safety profile of rilzabrutinib was consistent with that observed in previous studies. Regulatory submissions are planned in the United States and the European Union by the end of the year.
A serious autoimmune disease, IPT is characterized by the formation of antibodies that destroy platelets, and the disruption of platelet production leading to thrombocytopenia and increased bleeding episodes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction